CAncer, NUtrition and Taste 2 (CANUT-2)

October 9, 2023 updated by: Hospices Civils de Lyon

Impact of a Nutritional, Sensory and Culinary Support on the Improvement of the Quality of Life Related to Meals in Patients With Cancer Cancer Patients Treated With Chemotherapy

Although it has been established that the perception of food and eating and cooking habits change during cancer and its treatment, quality of life related to meals, which is an indicator of the psychobiological and physiological well-being of patients in their relationship to food, has been little studied in the pathological context, and particularly in patients undergoing chemotherapy.

Beyond its biological role, food plays a significant psychobiological and social role, as shown by a series of qualitative studies based on interviews with patients. Following a cancer diagnosis, loss of appetite, difficulty in sharing a meal with the family, and reduced pleasure in eating disrupt the patient's relationship with his or her food.

Thus, side effects such as fatigue, nausea and vomiting, and alterations in taste and smell induced by chemotherapy will affect patients' eating behavior, increasing the risk of deteriorating their quality of life with food. As these side effects are less known and therefore less expected by patients, they often lack the information and tools necessary to understand them.

The present study proposes a support for cancer patients treated by chemotherapy in order to improve their quality of life related to meals, and thus keep the pleasure of eating and reduce the risks of malnutrition. This support will consist of a guide provided to patients, in which they will have information on the functioning of the sensory systems involved in the eating experience, advice and culinary tips to adapt foods to their sensory disorders, and recipes that can be adapted in mild (for patients with hypersensitivity to tastes/smells), accentuated (for patients with hypersensitivity to tastes/smells) and enriched (for patients at risk of denutrition) versions. In addition, their sensory abilities will be assessed at the beginning of the study by psychophysical tests, then between each chemotherapy via a telephone interview (self-reported sensory abilities), and they will benefit from orientation according to the test results.

This work will be a first action to improve the quality of life related to the meal by information, follow-up, and adaptation of the meals to the sensory performances of each patient.

Study Overview

Study Type

Interventional

Enrollment (Actual)

209

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bron, France, 69677
        • Hôpital Louis Pradel, Service gynécologie
      • Bron, France, 69677
        • Hôpital Louis Pradel, Service pneumologie
      • Caluire-et-Cuire, France, 69300
        • Infirmerie Protestante
      • Lyon, France, 69004
        • Hôpital de la Croix Rousse, service pneumologie
      • Lyon, France, 69008
        • Centre Léon Bérard, service gynécologie
      • Lyon, France, 69008
        • Centre Léon Bérard, service pneumologie
      • Pierre-Bénite, France, 69310
        • Centre hospitalo-universitaire de Lyon Sud, service Oncologie médicale
      • Pierre-Bénite, France, 69310
        • Centre hospitalo-universitaire de Lyon Sud, service pneumologie
      • Saint-Étienne, France, 42270
        • CHU St Etienne,
      • Valence, France, 26 953
        • CH de Valence

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Major patient with one of the following 3 types of cancer:

    • Stage 4 lung cancer (TNM 7 or 8). The indication for immunotherapy in addition to first line chemotherapy will not be a criterion for non-inclusion patients
    • histologically or cytologically proven localized breast cancer cytologically proven
    • Gynecological cancer (ovarian cancer or uterine cancer) stage III-IV without functional digestive signs related to the tumor disease
  • Patient with a body mass index (BMI) between 18 Kg/m² and 35 Kg/m².
  • Patient for whom the indication for treatment with a first line of intravenous chemotherapy (+/- targeted therapy) has been accepted by multidisciplinary meeting.
  • Patient naive to previous chemotherapy.
  • Life expectancy > 3 months.
  • Patient with written informed consent
  • Patient affiliated to a French social security system.

Exclusion Criteria:

  • Patient under 18 years
  • Patient who had another malignancy within the last 3 years years, with the exception of carcinoma in situ of the cervix or cervical carcinoma in situ or adequately treated squamous cell carcinoma of the skin adequately treated, or basal cell skin cancer.This cancer must be adequately controlled.
  • Patients with symptomatic brain and/or meningeal metastases.
  • Patients with symptomatic mucositis.
  • Patients suffering or having suffered from an ear, nose and throat disease or oeso-gastro intestinal pathology interfering with the food intake.
  • Patients suffering from digestive disorders such as nausea prior to any cancer treatment.
  • Indication of concomitant radiotherapy or immunotherapy treatment alone.
  • Patients with a known food allergy or intolerance
  • Patient with diagnosed partial or total ageusia.
  • Patient with diagnosed partial or total anosmia.
  • Patient having used artificial feeding in the 2 months prior to inclusion.
  • Patient who has lost more than 10% of baseline weight in the 2 months prior to inclusion.
  • Patient unable to be regularly followed for any reason (geographical, family, social, psychological,...).
  • Patient deprived of liberty or placed under guardianship or legal protection.
  • Pregnant or breastfeeding woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: patients receiving CANUT support (guide + dietary interviews)

Patients included in this arm will have following interventions :

  • CANUT support : patients will receive the CANUT guide (food guide) to help them deal with eating disorders encountered during their chemotherapy treatment ; the CANUT support includes calls from a dietician between chemotherapy cycles for support and advice.
  • anthropometric measures
  • Prehension strength measurement
  • food quality of life questionnaire (Qualité de Vie Alimentaire QVA)
  • Quality of Life Questionnaire Core 30 (QLQ C30)
  • Scratch & Snif Test
  • Taste Strip Test
  • Nutrition interview
  • 24 H feed back questionnaire
  • condiment questionnaire
  • tobacco questionnaire
CANUT support includes delivery of the CANUT guide (food guide developed by Paul Bocuse Institute from previous results) ; it will be given to patient with explanations about the use of the guide. This also includes 2 calls from a dietician, performed between the 1st and the 3rd chemotherapy cycle to help patient personally with their food side effects.
These measures include weight, waist size, hip size and brachial circumference
Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
Food quality of life questionnaire
Quality of Life questionnaire Core 30
The Scratch & Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
This questionnaire describes patient's food and drink intakes during the last 24 ours
This questionnaire used to assess condiments consumption
This questionnaire used to assess tobacco consumption
This interview will be conducted by a dietician
Active Comparator: patients not receiving canut support (guide + dietary interviews)

Patients included in this arm will have following interventions :

  • anthropometric measures
  • Prehension strength measurement
  • food quality of life questionnaire (Qualité de Vie Alimentaire QVA)
  • Quality of Life Questionnaire Core 30 (QLQ C30)
  • Scratch & Snif Test
  • Taste Strip Test
  • Nutrition interview
  • 24 H feed back questionnaire
  • condiment questionnaire
  • tobacco questionnaire
These measures include weight, waist size, hip size and brachial circumference
Prehension strength will be assessed thanks to a hand grip device, that makes it possible to measure strength of all fingers, hands, wrists and forearms muscles
Food quality of life questionnaire
Quality of Life questionnaire Core 30
The Scratch & Snif Test is used to assess olfactory capacities : patient has to scratch a box on a card, smell it and recognize the scent amongst a list of propositions
The Taste Strip Test is used to assess taste capacities : strips impregnated with different concentrations of the 5 basic taste qualities (sweet, sour, acid, bitter, umami) are successively placed on patient's tongue ; patient has to identify the taste bit by bit.
This questionnaire describes patient's food and drink intakes during the last 24 ours
This questionnaire used to assess condiments consumption
This questionnaire used to assess tobacco consumption
This interview will be conducted by a dietician

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
QVA questionnaire score difference between the 2 arms
Time Frame: At the end of study follow-up, up to 12 weeks
The main endpoint of CANUT-2 is the comparison of the overall score of the food quality of life questionnaire (Qualité de Vie Alimentaire QVA) between patients who received CANUT support and those who did not receive the CANUT support. The comparison is performed at the time of V2 i.e. after 4 cycles of chemotherapy treatment, corresponding with the end of study follow-up.
At the end of study follow-up, up to 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
QVA questionnaire score
Time Frame: At the end of study follow-up, up to 12 weeks
Food questionnaire score QVA will be compared for each subsection between the 2 groups and between V1 (inclusion) and V2 (after 4 cycles of chemotherapy), according to the type of cancer.
At the end of study follow-up, up to 12 weeks
QLQ-C30 score
Time Frame: At the end of study follow-up, up to 12 weeks
Quality of life questionnaire score QLQ-C30 will be compared between the 2 arms and between V1 and V2, according to the type of cancer
At the end of study follow-up, up to 12 weeks
Weight
Time Frame: At the end of study follow-up, up to 12 weeks
Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer.
At the end of study follow-up, up to 12 weeks
waist size
Time Frame: At the end of study follow-up, up to 12 weeks
Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer.
At the end of study follow-up, up to 12 weeks
hip size
Time Frame: At the end of study follow-up, up to 12 weeks
Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer.
At the end of study follow-up, up to 12 weeks
brachial circumference
Time Frame: At the end of study follow-up, up to 12 weeks
Anthropometric parameters (weight, waist size, hip size and brachial circumference) associated with 24 H feedback questionnaire score and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer.
At the end of study follow-up, up to 12 weeks
Prehension strength
Time Frame: At the end of study follow-up, up to 12 weeks
This parameter, associated with anthropometric parameters and 24 H feedback questionnaire score, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer
At the end of study follow-up, up to 12 weeks
24 H feedback questionnaire score
Time Frame: At the end of study follow-up, up to 12 weeks
This parameter, associated with anthropometric parameters and prehension strength, will make it possible to assess evolution of nutritional status between the 2 arms and between V1 and V2, according to the type of cancer
At the end of study follow-up, up to 12 weeks
Olfactory capacities
Time Frame: At the end of study follow-up, up to 12 weeks
Olfactory capacities will be assessed thanks to the Scratch & Snif Test
At the end of study follow-up, up to 12 weeks
Taste capacities
Time Frame: At the end of study follow-up, up to 12 weeks
Taste capacities will be assessed thanks to the Taste Strip Test
At the end of study follow-up, up to 12 weeks
Trigeminal sensitivity
Time Frame: At the end of study follow-up, up to 12 weeks
Trigeminal sensitivity will be assessed thanks to a trigeminal sensitivity test
At the end of study follow-up, up to 12 weeks
Use of CANUT guide
Time Frame: At the end of study follow-up, up to 12 weeks
Changes in the frequency of use of the CANUT guide
At the end of study follow-up, up to 12 weeks
Patient satisfaction
Time Frame: At the end of study follow-up, up to 12 weeks
Determining patient satisfaction using a satisfaction questionnaire
At the end of study follow-up, up to 12 weeks
Patient typology
Time Frame: At the end of study follow-up, up to 12 weeks
Determining patient typology according to CITAS (Chemotherapy-induced Taste Alteration Scale) scale
At the end of study follow-up, up to 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 27, 2022

Primary Completion (Actual)

September 21, 2023

Study Completion (Actual)

September 21, 2023

Study Registration Dates

First Submitted

August 19, 2021

First Submitted That Met QC Criteria

August 24, 2021

First Posted (Actual)

August 30, 2021

Study Record Updates

Last Update Posted (Actual)

October 11, 2023

Last Update Submitted That Met QC Criteria

October 9, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Breast Cancer

Clinical Trials on CANUT support

3
Subscribe